(Q42697408)

5 November 2017

Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma (English)

1 reference

5 November 2017

2

Roman Rouzier

1 reference

5 November 2017

7

Emile Daraï

1 reference

5 November 2017

Claire Bonneau

1

1 reference

5 November 2017

Caroline Geyl

3

1 reference

5 November 2017

Annie Cortez

4

1 reference

5 November 2017

Mathieu Castela

5

1 reference

5 November 2017

Raphael Lis

6

1 reference

5 November 2017

Cyril Touboul

8

1 reference

5 November 2017

language of work or name

English

0 references

publication date

1 November 2014

1 reference

5 November 2017

1 reference

5 November 2017

136

1 reference

5 November 2017

1

1 reference

5 November 2017

112-120

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

5 November 2017

1 reference

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

Management strategies for recurrent platinum-resistant ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

Environment-mediated drug resistance: a major contributor to minimal residual disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

Human ovarian carcinoma–associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

IL-6 involvement in epithelial cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

Identification and characterization of ovarian cancer-initiating cells from primary human tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

Review of a personal experience in the management of carcinomatosis and sarcomatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

Extracellular matrix of ovarian tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

CD44: structure, function, and association with the malignant process.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

Hyaluronan oligosaccharides sensitize lymphoma resistant cell lines to vincristine by modulating P-glycoprotein activity and PI3K/Akt pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

Interaction between CD44 and hyaluronate induces chemoresistance in non-small cell lung cancer cell

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

Hyaluronan oligomers-HPMA copolymer conjugates for targeting paclitaxel to CD44-overexpressing ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

Interleukin-6 receptor enhances early colonization of the murine omentum by upregulation of a mannose family receptor, LY75, in ovarian tumor cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6 secretion in an amniochorionic membrane based 3D model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.024

10.1016/J.YGYNO.2014.10.024

7 January 2021

Identifiers

DOI

1 reference

5 November 2017

1 reference